Quiz: Pulmonary Hypertension Questions With Answers

16 Questions | Attempts: 2449
Share

SettingsSettingsSettings
Quiz: Pulmonary Hypertension Questions With Answers - Quiz

Play this quiz on pulmonary hypertension questions with answers to gauge your knowledge on the topic. The quiz contains various facts, trivia, and conceptual questions that will help you in mastering the subject. The quiz is thoroughly researched, providing easy, medium, and hard-level questions that are sure to provide you with valuable feedback and would also enhance your knowledge reservoir. If you like the quiz, share it with your friends and family. All the best!


Questions and Answers
  • 1. 
    Which of the following regarding treprostinil is FALSE?
    • A. 

      It has a longer half-life than epoprostenol

    • B. 

      It is also shown to have a survival benefit

    • C. 

      It has a higher cost than epoprostenol

    • D. 

      It is stable at room temperature without a need for a back-up cassette.

    • E. 

      It is a prostacyclin analog

  • 2. 
    Which of the following correctly represents the target INR range for a patient with PAH on warfarin?
    • A. 

      1.0 - 2.0

    • B. 

      1.5 - 2.5

    • C. 

      2.0 - 3.0

    • D. 

      2.5 - 3.5

  • 3. 
    What can pharmacists contribute in the therapy of PAH?
    • A. 

      Medication safety

    • B. 

      Optimizing medical regimens

    • C. 

      Patient education and adherence

    • D. 

      Quality improvement

  • 4. 
    Which of the following regarding the treatment of PAH is FALSE?
    • A. 

      There is a large amount of long-term data for the therapies of PAH

    • B. 

      Prostacyclin dosage forms must be considered

    • C. 

      Costs and convenience must be considered

    • D. 

      Pharmacists are important in the therapy

  • 5. 
    Which of the following regarding PAH is FALSE?
    • A. 

      Vasoconstriction is an issue

    • B. 

      Vascular wall remodeling is an issue

    • C. 

      There is a cure for PAH

    • D. 

      The balance of vasoconstriction and vasodilation may indicate PAH

  • 6. 
    Treprostinil, similar to epoprostenol, has two products.
    • A. 

      True

    • B. 

      False

  • 7. 
    All of the following are true regarding macitentan EXCEPT
    • A. 

      It is safe to use in pregnant women

    • B. 

      It is a tissue selective ET-1 receptor antagonist

    • C. 

      Hepatotoxicity is a concern

    • D. 

      Drug interactions are a cocnern

  • 8. 
    Regarding iloprost, which of the following is FALSE?
    • A. 

      It is a prostacyclin analog

    • B. 

      It is approved for PAH WHO class 3 or 4 symptoms

    • C. 

      Very few doses are given per day

    • D. 

      There is a significant improvement in 6MWD and hemodynamics

  • 9. 
    All of the following are true regarding calcium channel blockers (CCBs) in PAH EXCEPT
    • A. 

      CCBs have a selective effect on vascular smooth muscle

    • B. 

      Normal physiologic doses are sufficient for treatment purposes

    • C. 

      Adverse effects must be considered

    • D. 

      Long-term clinical response is less than 10%

  • 10. 
    Which of the following regarding bosentan is TRUE?
    • A. 

      It is an ET-1 receptor agonist

    • B. 

      It is safe to use in pregnant women

    • C. 

      It is highly selective for the endothelin A (ETa) receptor

    • D. 

      It has many drug interactions

  • 11. 
    Which of the following statements regarding the comparison between sildenfail and tadalafil in the context of PAH is FALSE?
    • A. 

      Sildenafil is shorter-acting while tadalafil is longer-acting

    • B. 

      Sildenafil is TID dosing while tadalafil is QD dosing

    • C. 

      Flushing and hypotension are two concerns with both drugs

    • D. 

      Exercise ability is improved with both drugs

    • E. 

      Nitrates can be safely used with both drugs

  • 12. 
    Which of the following regarding pulmonary arterial hypertension (PAH) is FALSE?
    • A. 

      The disease affects men much more than women

    • B. 

      Non-specific symptoms such as fatigue and edema present clinically

    • C. 

      Catheterization is required when PH is suspected

    • D. 

      Underlying causes and PCWP or LVEDP are evaluated

  • 13. 
    Which of the following regarding pulmonary hypertension (PH) is FALSE?
    • A. 

      PH has many underlying etiologies

    • B. 

      The disease affects the left side of the heart

    • C. 

      The hemodynamic definition of PH is a mean pulmonary arterial pressure (PAP) greater than or equal to 25 mmHg

    • D. 

      Pulmonary arterial hypertension (PAH) is a subset of PH

  • 14. 
    Which of the following regarding epoprostenol is FALSE?
    • A. 

      The drug is a prostacyclin analog

    • B. 

      There are two products: Flolan and Veletri

    • C. 

      The drug improves mortality

    • D. 

      The drug is selective

  • 15. 
    Which of the following regarding ambrisentan is FALSE?
    • A. 

      It is a non-selective ETa antagonist

    • B. 

      Teratogenicity is an issue

    • C. 

      Drug interactions are still concerning

    • D. 

      All of the above

  • 16. 
    The following statements are true regarding riociguat EXCEPT
    • A. 

      It is a soluble guanylate cyclase (sGC) stimulator

    • B. 

      It can be used in patients with renal failure

    • C. 

      Teratogenicity and hepatotoicity are concerns

    • D. 

      There are many drug interactions

Back to Top Back to top
×

Wait!
Here's an interesting quiz for you.

We have other quizzes matching your interest.